About
Psilocybin Therapy
Areas of Focus
Categories
Small Molecule PharmaceuticalPsychedelic
Team (15)
Annalisa Jenkins MBBS
Independent Director
Compass Pathways
board_member
Daphne Karydas MBA
Independent Director
Compass Pathways
board_member
David Norton
Independent Director
Compass Pathways
board_member
Dr Guy Goodwin
Chief Medical Officer
Compass Pathways
executive
Dr Michael Gold
Chief Research and Development Officer
Compass Pathways
team_member
Dr Steve Levine
Chief Patient Officer
Compass Pathways
team_member
Clinical Trials (16)
View allTotal Trials
16
As Lead Sponsor
8
As Collaborator
8
Total Enrollment
1,691
By Phase
PHASE3: 3PHASE2: 11NA: 1
By Status
COMPLETED: 8ACTIVE_NOT_RECRUITING: 3RECRUITING: 2UNKNOWN: 2WITHDRAWN: 1
Clinical Trials Pipeline16 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06247839Collaborator
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
PHASE3Recruiting
20 participants
Started: Sep 10, 2024 · Completed: Jun 30, 2026
NCT05711940Lead Sponsor
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
PHASE3Recruiting
568 participants
Started: Feb 14, 2023 · Completed: Dec 31, 2026
NCT05733546Lead Sponsor
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
PHASE2Active, not recruiting
102 participants
Started: Jan 30, 2023 · Completed: Sep 30, 2025
NCT05624268Lead Sponsor
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
PHASE3Active, not recruiting
255 participants
Started: Jan 19, 2023 · Completed: Apr 30, 2026
NCT05481736Lead Sponsor
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
PHASE2Completed
32 participants
Started: Oct 12, 2022 · Completed: Nov 18, 2024
Locations (1)
Headquarters
Cheshire, UK
Map
Loading map...